Loading
LYRIC adds an 'indeterminate response' to the lymphoma response rules for immunotherapy, so that apparent growth from a flare is not mistaken for failure before a biopsy or later scan settles it.
Checkpoint inhibitors and other immunomodulatory drugs can cause tumour flare or pseudoprogression in lymphoma, and calling that progressive disease could take patients off a treatment that is working. A workshop (Cheson and colleagues, Blood 2016) gave provisional recommendations modifying the Lugano criteria for these drugs in trials, introducing indeterminate response for such lesions until biopsy or later imaging confirms flare or true progression.
Showing the technology this term belongs to: Immune checkpoint inhibitors.
Shares iRECIST (response criteria for immunotherapy trials), Progressive disease and radiographic progression, Complete response (CR) and partial response (PR), Immune checkpoint inhibitors.
Shares Complete response (CR) and partial response (PR), Lugano classification / Ann Arbor staging, Non-Hodgkin lymphoma (all types).
Shares Complete response (CR) and partial response (PR), Lugano classification / Ann Arbor staging.
Shares Complete response (CR) and partial response (PR), FDG PET.
Shares Complete response (CR) and partial response (PR), Lugano classification / Ann Arbor staging.
Shares iRECIST (response criteria for immunotherapy trials), Immune checkpoint inhibitors.
Shares Lugano classification / Ann Arbor staging, Hodgkin lymphoma.
Shares iRECIST (response criteria for immunotherapy trials), Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/